Binnopharm Group, a subsidiary of AFK Sistema, has announced its strategic move into the women’s health market by developing and launching a new series of gynecological drugs. Among the new offerings, a medication designed to treat endometriosis has already become available in pharmacies. In addition, four more therapies are at the final stage of registration or have already obtained registration certificates. By the end of 2030, the domestic manufacturer aims to sell these medicines worth over 18 billion rubles, the company’s press service told GxP News.
“The gynecological product line of Binnopharm Group in 2025 comprises five specially developed medications designed to address the key needs of women’s health. <…> In the near future, we plan to gradually introduce the remaining four products to the market. Additionally, in 2026, we aim to launch two more new formulations, with ongoing efforts to expand and develop our range further,” said Ekaterina Slavgorodskaya, Director of Sales and Promotion at Binnopharm Group.
The company added that the product line was developed with consideration of the key needs of the female body, spanning from adolescence to menopause. In order to promote the product line, the manufacturer is focusing on partnerships with top medical associations and specialists in gynecology.
Earlier, Binnopharm Group reported a 33% increase in export sales in the first quarter of 2025, reaching 1 billion rubles. The growth rate outpaced the broader export pharmaceutical market by 19%. During the reporting period, Binnopharm became the leading domestic drug manufacturer in Kyrgyzstan and ranked in the top three in Kazakhstan, Georgia, and Uzbekistan.
